Name: CJC-1295 with DAC 5 mg
Brand: Peptide Revolution
SKU: 8737
Price: 75.5 EUR
Availability: BackOrder
Rating: 5 (1 reviews)

Find out what benefits peptides have

Discover how peptides can boost recovery, improve skin health, increase energy and support overall performance. Explained simply and clearly in this short video.

Product Description

Research Peptide · Long-Acting GHRH Analog

CJC-1295 with DAC 5 mg

Research-grade lyophilized powder supplied in a sealed glass vial. Each vial contains CJC-1295 with DAC 5 mg, a synthetic GHRH analogue incorporating Drug Affinity Complex (DAC) technology, studied in controlled experimental models of sustained growth-hormone release, the IGF-1 axis, and long-acting peptide pharmacokinetics.

Research Use Only

This product is intended strictly for laboratory and scientific investigation. Not for human consumption, therapeutic use, or veterinary application.

Specifications

Purity

High-purity research grade

Form

Lyophilized powder

Content

CJC-1295 with DAC 5 mg per vial

Technology

Drug Affinity Complex (DAC) — albumin-binding, extended half-life

Packaging

Sealed glass vial with sterile stopper

Storage

Store desiccated at 2–8 °C, protected from light

Molecular Formula

C165H269N47O46

Molecular Weight

≈ 3647.1 g/mol

CAS Number

863288-34-0 (base peptide)

Reconstitution

In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC), supporting controlled preparation and research-only handling procedures.

For a compatible research-only solvent, see Bacteriostatic Water – 10 ml.

Research Overview

CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone that incorporates a Drug Affinity Complex (DAC), enabling covalent binding to serum albumin and substantially extending its circulating half-life relative to the non-DAC form. Studied in metabolic and endocrine research, it is investigated for sustained GHRH-receptor agonism, prolonged growth-hormone output, and modulation of the IGF-1 axis in controlled experimental settings. Its long-acting profile also makes it a common model for peptide pharmacokinetics. No therapeutic or clinical claims are made or implied.